The macrophage activation syndrome is brought under control by emapalumab.

Published Date: 04 May 2023

In a phase 2 study, patients receiving emapalumab after high-dose glucocorticoids failed to control their macrophage activation syndrome (MAS) secondary to systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still's disease (AOSD).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot